BioPharmX Prices Secondary Offering
BioPharmX saw its shares take a sharp downward turn following the announcement of a secondary offering.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 219
Inovio Fails to Impress With HPV Business Update
Inovio Pharmaceuticals made waves early on Tuesday morning following an update for its human papillomavirus (HPV) treatment.
8 Major Biopharma Events Coming Later in 2016 and in 2017
FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in 2016 or 2017.
Why Merrill Lynch Sees Acadia Rising Another 60%
Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) surged early on Monday morning. This company is under the spotlight by the U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee, which is set to review data…
Apricus Bio Top-Line Results Don’t Stand Up to Expectations
Apricus Biosciences announced top-line results from the Phase 2b proof-of-concept study of fispemifene in men with secondary hypogonadism and sexual dysfunction.
Alder Biopharma Soars on Positive Mid-Stage Trial Results
Alder Biopharmaceuticals announced positive top-line data from two clinical trials evaluating its proprietary monoclonal antibody product candidate for migraine prevention.
Tactile Systems Prepares for IPO
Tactile Systems Technology has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
5 Key Biopharma Movers From Last Week
Over the past week, Akorn, Celator Pharmaceuticals and a few other biotech companies made impressive runs.
Top 4 Medtech Picks From Merrill Lynch
Merrill Lynch has some ideas about how to take advantage of the trends in health care going forward.
Celator Pharma Prices Secondary Offering
Celator Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
Vitae Pharma Prepares for Secondary Offering
Vitae Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering valued at up to $40 million.
Portola Pharma Top-Line Results Miss Par for the Course
Portola Pharmaceuticals made waves early on Thursday morning with less than favorable top-line results.
Jefferies Identifies 5 Top Biotech Stocks for Huge Upside
Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.
How Ionis Pharma Beat a Biotech Giant
Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.
Akorn Back on Track to Restate Results
Akorn reported its preliminary 2015 financial results before the markets opened on Tuesday and issued guidance for the 2016 full year.